NCT00511108View on ClinicalTrials.gov

Sitagliptin and Pioglitazone Mechanism of Action Study in Type 2 Diabetes Mellitus (0431-061)

PHASE1CompletedINTERVENTIONAL
Enrollment

211

Participants

Timeline

Start Date

July 11, 2007

Primary Completion Date

February 24, 2009

Study Completion Date

February 24, 2009

Conditions
Type 2 Diabetes Mellitus (T2DM)
Interventions
DRUG

Comparator: sitagliptin phosphate

sitagliptin phosphate 100 mg as oral tablets. Each patient will be administered 1 tablet once daily.

DRUG

Comparator: pioglitazone

pioglitazone 30 mg will be supplied as oral tablets. Each patient will be administered 1 tablet once daily.

DRUG

Comparator: placebo to pioglitazone

pioglitazone 30 mg placebos will be supplied as oral tablets. Each patient will be administered 1 tablet once daily.

DRUG

Comparator: placebo to sitagliptin

sitagliptin phosphate 100 mg placebos will be supplied as oral tablets. Each patient will be administered 1 tablet once daily.

All Listed Sponsors
lead

Merck Sharp & Dohme LLC

INDUSTRY

NCT00511108 - Sitagliptin and Pioglitazone Mechanism of Action Study in Type 2 Diabetes Mellitus (0431-061) | Biotech Hunter | Biotech Hunter